ArticlePloS one2025

Long term cost-effectiveness analysis of IDegLira in the treatment of type 2 diabetes patients compared to GLP-1RA added to basal insulin after IDegLira entered the national reimbursement drug list in China.

Dunming Xiao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.